The diacylglycerol O-acyltransferase 1 (DGAT1) antibody is a key tool for studying DGAT1. an enzyme critical for triglyceride synthesis. DGAT1 catalyzes the final step in the glycerolipid biosynthesis pathway, transferring a fatty acyl group to diacylglycerol to form triglycerides. It is highly expressed in tissues with active lipid metabolism, such as the small intestine, liver, and adipose tissue. DGAT1's role in lipid storage and metabolism links it to metabolic disorders, including obesity, diabetes, and cardiovascular diseases. Research also highlights its involvement in cellular lipid droplet formation and membrane biosynthesis. Unlike DGAT2. its isoform, DGAT1 localizes to the endoplasmic reticulum and has distinct substrate preferences. DGAT1 antibodies, typically polyclonal or monoclonal, enable detection and quantification of the enzyme in techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies are vital for investigating DGAT1's physiological functions, its regulatory mechanisms, and its potential as a therapeutic target. Notably, DGAT1 inhibitors are being explored for treating metabolic syndromes, while DGAT1 mutations are associated with congenital diarrhea disorders. The antibody's specificity and validation in diverse experimental models make it indispensable for both basic research and drug development studies.